1
It is a devastating and intractable disease with a poor outcome.
2
A conditional logistic regression analysis confirmed an independent effect of age at diagnosis on ileal disease and surgery for intractable disease.
3
Our work identifies and validates USP18 as a pancreatic cancer oncogene and provides a potential druggable target for this intractable disease.
4
The findings hold great promise for the development of new treatments for intractable diseases.
5
A number of these early lethal intractable diseases also present devastating irreversible pathology at birth or soon after.
1
Conclusion: SLE patients with delayed treatment and refractory disease have poorer prognosis.
2
The outcome of patients with multiply relapsed or cisplatin- refractory disease remains particularly poor.
3
Fifteen were sensitive relapses of poor prognosis, 11 initially refractory disease.
4
In testicular cancer, paclitaxel has initially been tested in patients with cisplatin- refractory disease.
5
The impact is greater in patients with greater disease severity, comorbidities, or refractory disease.
6
We assessed the efficacy and safety of ibrutinib in a population with rituximab- refractory disease.
7
Patients with refractory disease did not benefit from high-dose chemotherapy.
8
Patients and methods: Patients were eligible at first relapse or first designation of refractory disease.
9
While corticosteroids and disease-modifying anti-rheumatic drugs improve outcomes, there remain children who experience refractory disease.
10
Newer therapies are needed to improve the outcomes of patients with poor-risk primary refractory disease.
11
However, its role in the treatment of patients with primary refractory disease is not well defined.
12
Further studies are needed to characterize the role of cystectomy in treatment- refractory disease from radiation therapy.
13
Forty-eight patients were treated of which 71% had refractory disease.
14
Vitiligo is a common and refractory disease worldwide.
15
Although cisplatin is used routinely in treating bladder cancer, refractory disease remains lethal for many patients.
16
In prostate cancer, estramustine phosphate is widely used as palliative treatment for patients with hormone- refractory disease.
